AU2007311026B2 - Talarazole metabolites - Google Patents

Talarazole metabolites Download PDF

Info

Publication number
AU2007311026B2
AU2007311026B2 AU2007311026A AU2007311026A AU2007311026B2 AU 2007311026 B2 AU2007311026 B2 AU 2007311026B2 AU 2007311026 A AU2007311026 A AU 2007311026A AU 2007311026 A AU2007311026 A AU 2007311026A AU 2007311026 B2 AU2007311026 B2 AU 2007311026B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
compound according
acceptable salt
talarozole
metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007311026A
Other languages
English (en)
Other versions
AU2007311026A1 (en
Inventor
Debra Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Laboratories Inc
Original Assignee
Stiefel Research Australia Pty Ltd
Stiefel Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Research Australia Pty Ltd, Stiefel Laboratories Inc filed Critical Stiefel Research Australia Pty Ltd
Publication of AU2007311026A1 publication Critical patent/AU2007311026A1/en
Assigned to STIEFEL LABORATORIES, INC. reassignment STIEFEL LABORATORIES, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: BARRIER THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2007311026B2 publication Critical patent/AU2007311026B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007311026A 2006-10-17 2007-10-17 Talarazole metabolites Ceased AU2007311026B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (2)

Publication Number Publication Date
AU2007311026A1 AU2007311026A1 (en) 2008-04-24
AU2007311026B2 true AU2007311026B2 (en) 2012-05-17

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007311026A Ceased AU2007311026B2 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Country Status (10)

Country Link
US (2) US8188124B2 (enExample)
EP (1) EP2114895A4 (enExample)
JP (1) JP5343267B2 (enExample)
KR (1) KR101419965B1 (enExample)
CN (1) CN101611016B (enExample)
AU (1) AU2007311026B2 (enExample)
BR (1) BRPI0718310A2 (enExample)
CA (1) CA2667053C (enExample)
MX (1) MX2009004096A (enExample)
WO (1) WO2008049027A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
ATE523585T1 (de) 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
CA2959401C (en) 2008-02-21 2021-12-07 Centocor Ortho Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
KR101651661B1 (ko) 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
MX2011004563A (es) 2008-10-31 2011-06-01 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
PL2366021T3 (pl) 2008-11-20 2017-12-29 Janssen Biotech, Inc. Hodowla pluripotencjalnych komórek macierzystych na mikronośnikach
PL2366022T3 (pl) 2008-11-20 2016-11-30 Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych
KR20170118969A (ko) 2009-07-20 2017-10-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
AU2010333839C1 (en) 2009-12-23 2016-07-21 Janssen Biotech Inc. Differentiation of human embryonic stem cells
CN107189979B (zh) 2010-03-01 2021-05-04 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
KR101986176B1 (ko) 2010-05-12 2019-06-05 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
AU2011296381B2 (en) 2010-08-31 2016-03-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030539A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030540A2 (en) * 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
US9388386B2 (en) 2011-12-22 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
WO2013184888A1 (en) 2012-06-08 2013-12-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
WO2014105543A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
RU2684215C2 (ru) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
JP6705911B2 (ja) 2016-04-14 2020-06-03 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の中腸内胚葉細胞への分化

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486187B1 (en) * 1996-06-27 2002-11-26 Janssen Pharmaceutica N.V. N-[4-(heteroarylmethyl)phenyl]-heteroarylamines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
IL162533A0 (en) * 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486187B1 (en) * 1996-06-27 2002-11-26 Janssen Pharmaceutica N.V. N-[4-(heteroarylmethyl)phenyl]-heteroarylamines

Also Published As

Publication number Publication date
BRPI0718310A2 (pt) 2013-11-19
EP2114895A1 (en) 2009-11-11
JP2010506953A (ja) 2010-03-04
CN101611016B (zh) 2012-01-25
CA2667053A1 (en) 2008-04-24
MX2009004096A (es) 2009-06-16
JP5343267B2 (ja) 2013-11-13
US20100292284A1 (en) 2010-11-18
US20120283204A1 (en) 2012-11-08
US8188124B2 (en) 2012-05-29
AU2007311026A1 (en) 2008-04-24
WO2008049027A1 (en) 2008-04-24
KR20090068286A (ko) 2009-06-25
EP2114895A4 (en) 2011-06-22
US8399495B2 (en) 2013-03-19
CA2667053C (en) 2015-04-28
KR101419965B1 (ko) 2014-07-16
CN101611016A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
CA2667053C (en) Talarazole metabolites
DE60106281T2 (de) Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
AU2020368393A1 (en) Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
KR101430626B1 (ko) 부프레노르핀 유도체 및 이들의 용도
US12162902B2 (en) Decarboxylase inhibitors for treating Parkinson's disease
US20150148370A1 (en) Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
EP4089088A1 (en) Mor receptor agonist compound, preparation method therefor, and use thereof
Ng et al. Replacement of 3'-CH group by nitrogen in the carbocyclic analog of thymidine
US9682990B2 (en) Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
JP2005510568A (ja) アリール基が結合したアザポリサイクリック化合物
EP1698338B1 (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
CN115003661B (zh) 芳基葡糖苷衍生物及其在药物中的用途
CZ20021435A3 (cs) Pro-léčiva 6-methoxy-2-naftyloctové kyseliny
US20250129055A1 (en) Glucoside derivative, and preparation method therefor and application thereof
CN121342759A (zh) 二氢喹唑啉酮类化合物及其制备方法和应用
ES2794560T3 (es) Derivado de amina cíclica y utilización farmacéutica del mismo
KR820001304B1 (ko) 펜아탄올아민의 제조방법
JPH0689020B2 (ja) グリゼオール酸のモノエステル誘導体
CN87103608A (zh) 苯并噻嗪二氧化物衍生物
CA2518100A1 (en) Use of non-immunosuppressive pipecolic acid derivatives for inducing chondrogenic differentiation
HK40007517B (en) Immunomodulator compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired